Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy' Rating
A closeup of pills in a pharmacy, representing the high quality medications of the company.
Despite early-year challenges, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) remains a 'Buy'.
On July 22, 2025, Morgan Stanley maintained its 'Buy' rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165. The analyst attributes its bullish stance to its expectation that the company will bounce back in the second half of the year, following a 10% miss in its Q1 net product sales. This expectation is driven by an extra shipping week in the Oncology segment, stronger demand for Rylaze due to pediatric protocol shifts, and seasonal strength in sleep disorder medication.
Meanwhile, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is expected to experience major clinical developments with HERIZON-GEA-01 data and the anticipated dordaviprone FDA decision. Furthermore, the upcoming leadership change boosts optimism. Looking ahead, the analyst's oncology revenue estimate exceeds the street's estimates.
On the other hand, Wells Fargo reinforced this outlook, maintaining a 'Buy' rating on July 18 with a price target of $170.
Operating in the United States, Europe, and other global markets, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products. It remains on our list of the most undervalued stocks.
While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
AMD Stock Gets Bullish Re-Rating as Export Ban Relief Sparks $800M Upside
Advanced Micro Devices, Inc. (NASDAQ:) is one of the . On July 30, Susquehanna analyst Christopher Rolland raised the price target on the stock to $210 from $135 and kept a 'Positive' rating on the shares. After previewing Q2 results, the analysts anticipate generally in-line to slightly better results on the back of stronger PC sales. This is because Intel acknowledged that tariff-related pull-ins continued in 2Q. The firm has also highlighted that AMD boasts server business strength. It has been gaining market share in EPYC data center CPUs. A major factor behind the upgraded outlook on AMD is that the government announced in July that it would review and likely renew AMD's license application for exporting MI308 AI chips to China. A close up of a complex looking PCB board with several intergrated semiconductor parts. Provided this occurs, it would help in reversing the previously anticipated $1.5 billion negative revenue impact from China restrictions. As of now, the firm expects AMD to recover an estimated $800 million in revenue during the second half of 2025 from the potential China sales. It also highlighted that much of the $800 million in MI308 inventory that AMD was planning to write down may now be sold at near-zero cost. Advanced Micro Devices, Inc. (NASDAQ:AMD) develops and sells semiconductors, processors, and GPUs for data centers, gaming, AI, and embedded applications. While we acknowledge the potential of AMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Palo Alto Networks (PANW) to Acquire CyberArk in $25 Billion AI Security Deal
Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the . On July 30, Reuters reported that Palo Alto Networks has agreed to buy Israeli peer CyberArk Software for an estimated $25 billion, its biggest deal yet. CEO Nikesh Arora strives to develop a comprehensive cyber security provider to capitalize on AI-driven demand. The cash-and-stock deal is one of the largest technology deals of the year. By acquiring CyberArk, Palo Alto will be able to broaden its cybersecurity services, adding identity security tools, and enhancing its appeal to large enterprise customers. A young professional in a workspace with a laptop demonstrating the company's anti-virus security & privacy protection services. 'The rise of AI and the explosion of machine identities have made it clear that the future of security must be built on the vision that every identity requires the right level of privilege controls.' -Arora said in a statement. Palo Alto Networks, Inc. (NASDAQ:PANW) is a leader in AI-powered cybersecurity. While we acknowledge the potential of PANW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Apple (AAPL) Poised for Major Cash Windfall Thanks to Big Beautiful Bill
Apple Inc. (NASDAQ:AAPL) is one of the . On July 30, Morgan Stanley reiterated the stock as 'Overweight.' According to the firm, One Big Beautiful Bill Act (OBBBA) will offer a significant boost to free cash flow (FCF) across the IT hardware sector. It noted that Apple is one of the big beneficiaries of the Big Beautiful bill. 'We estimate the One Big Beautiful Bill Act (OBBBA) can add 12% upside to our IT Hardware coverage FCF in 2025, and 5%, on average, annually, to our coverage over the next 4 years,' Through the bill, companies will be able to immediately deduct R&D and capital investment expenses from U.S. taxes. This will accelerate their tax savings and increase near-term cash flow. 'We estimate that over the next 4 years, the [One Big Beautiful Bill] will add a cumulative $20.3B of upside to our AAPL [free-cash flow] forecast, all else equal, which equates to an average annual FCF tailwind of 4%.' The firm projects the legislation will generate more than $12 billion in incremental cash flow for covered names over the next year, as well as $20 billion cumulatively over four years. 'This benefit is mostly about timing, as it pulls forward future tax savings rather than changing the long-term cash flow picture,' the analysts said. Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
